{
    "clinical_study": {
        "@rank": "72006", 
        "arm_group": [
            {
                "arm_group_label": "Without Interstitial lung disease (ILD)"
            }, 
            {
                "arm_group_label": "With Interstitial lung disease (ILD)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a mechanistic research study to evaluate the relationship between cough, reflux, and\n      aspiration in patients with systemic sclerosis (scleroderma)."
        }, 
        "brief_title": "Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Scleroderma Lung", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Scleroderma, Localized", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients \u2265 18 years old.\n\n          -  Fulfilling the American College of Rheumatology criteria for SSc.\n\n          -  For ILD subgroup (n=6):\n\n               -  An upright chest-roentgenogram (chest x-ray) is abnormal and compatible with an\n                  interstitial lung disease.\n\n               -  HRCT of the chest confirms the presence of bilateral reticular, ground glass,\n                  and/or honeycomb abnormalities that is otherwise unexplained by an alternative\n                  process\n\n               -  The HRCT fibrosis score must be \u2265 7.\n\n               -  The total lung capacity (TLC, measured by body plethysmography) and/or the\n                  diffusing capacity of the lung for carbon monoxide (DLCO) is below the predicted\n                  normal.\n\n               -  The forced vital capacity (FVC) is reduced below the predicted normal.\n\n               -  The patient is symptomatic (i.e. dyspnea and/or a chronic cough) for more than 8\n                  weeks that is otherwise unexplained by an alternative mechanism.\n\n          -  For No ILD subgroup (n=6):\n\n               -  No radiographic evidence of ILD on plain chest x-ray.\n\n               -  The HRCT fibrosis score, when performed) must be < 7\n\n               -  The TLC and FVC are within their predicted normal.\n\n               -  The DLCO is within the predicted normal, except when reduced in isolation by\n                  pulmonary hypertension.\n\n        Exclusion Criteria:\n\n          -  Active smoking within the 6 months.\n\n          -  Pneumonia or bronchitis in past 4 weeks.\n\n          -  Active acute illness such as uncontrolled heart failure, infection, or asthma.\n\n          -  Use of more than 3 liters per minute (LPM) of oxygen by nasal cannula at rest.\n\n          -  Coordinator, investigator, or clinician concerns on the patient's compliance, safety,\n             or in ability to complete study requirements.\n\n          -  Morbid condition not expected to live more than 1 year.\n\n          -  Alternative cause or diagnosis for the patient's ILD besides SSc.\n\n          -  Pregnancy.\n\n          -  Obstructive lung disease with an FEV1 (forced expiratory volume in 1 second) to FVC\n             ratio less than 0.7, nor radiographic evidence of emphysema on CT.\n\n          -  Planned therapeutic procedures involving the esophagus (e.g. dilation, surgery) prior\n             to completion of study tests"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All consecutive adult patients seen at the Mayo Clinic in Florida with a confirmed\n        diagnosis of systemic sclerosis (SSc) will be eligible."
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667042", 
            "org_study_id": "12-000304"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Scleroderma Lung", 
            "Gastroesophageal Reflux", 
            "Microaspiration", 
            "Cough"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "email": "ruday.kellie@mayo.edu", 
                "last_name": "Kellie Ruday", 
                "phone": "904-953-7766"
            }, 
            "facility": {
                "address": {
                    "city": "Jacksonville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32224"
                }, 
                "name": "Mayo Clinic in Florida"
            }, 
            "investigator": {
                "last_name": "Augustine Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough", 
        "overall_contact": {
            "email": "ruday.kellie@mayo.edu", 
            "last_name": "Kellie Ruday", 
            "phone": "904-953-7766"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Augustine Lee, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cross-sectional comparison between airway pepsin level, cough frequency, FVC, DLCO, and CT fibrosis score", 
            "measure": "Airway pepsin concentration", 
            "safety_issue": "No", 
            "time_frame": "cross-sectional"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Augustine S. Lee", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}